Literature DB >> 9401084

Granulocyte colony-stimulating factor given in addition to interferon-alpha to mobilize peripheral blood stem cells for autologous transplantation in chronic myeloid leukaemia.

E Archimbaud1, M Michallet, I Philip, C Charrin, G Clapisson, A Belhabri, F Guilhot, P Stryckmans, P Adeleine, D Fière.   

Abstract

In order to potentially mobilize and harvest the Ph cells observed in most patients with chronic myeloid leukaemia (CML) during interferon-alpha (IF-alpha) therapy, G-CSF (filgrastim), 5 microg/kg/d, was administered subcutaneously together with IF-alpha to 30 CML patients in haematological remission but with various degrees of cytogenetic remission, after IF-alpha therapy. Peripheral blood stem cells (PBSC) were harvested using standard aphereses from day 5 of G-CSF Patients underwent one to four (median three) aphereses. Median total yields/kg were 7.6 (range 3.8-25) x 10(8) MNC, 3.4 (0-140) x 10(6) CD34+ cells, and 17 (1.1-107) x 10(4) CFU-GM. No patient had a significant increase in the percentage of Ph+ cells in the bone marrow under G-CSF therapy. The percentage of Ph+ cells in apheresis products tended to decrease between the first and the last apheresis (P = 0.05). 14 patients who were not responsive to IF-alpha were transplanted after conditioning with busulphan 16 mg/kg and melphalan 140 mg/m2. Median time to neutrophils > 0.5 x 10(9)/l was 20 d (16-114 d) and to platelets > 50 x 10(9)/l 18 d (12-149 d). Nine patients had a major cytogenetic response post graft, which correlated with the amount of Ph+ cells reinfused with the graft (P = 0.02). We conclude that this procedure is feasible, allowing the harvest of enough PBSC, some of them Ph- in patients who responded to IF-alpha, to allow autologous transplantation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9401084     DOI: 10.1046/j.1365-2141.1997.4483258.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  1 in total

1.  Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.

Authors:  Qaiser Bashir; Marcos J De Lima; John D McMannis; Guillermo Garcia-Manero; Elizabeth Shpall; Hagop Kantarjian; Jorge E Cortes; Susan M O'Brien; Dan Jones; Muzaffar Qazilbash; Wei Wei; Sergio A Giralt; Richard E Champlin; Chitra Hosing
Journal:  Leuk Lymphoma       Date:  2010-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.